The MAESTRIA Consortium, which consists of 18 partners from different European countries, met for the 3rd time on 8 and 9 May to discuss the progress of the EU-funded MAESTRIA project.
From May 5 to 7, 2025, the 10th AFNET EHRA Consensus Conference took place in Gressy, France. Below are some impressions of the presentations, breakout sessions and the program around it
Prof. Dr. med. Götz Thomalla (UKE) and Dr. med. Märit Jensen (UKE) have recorded a video on the new EAST-STROKE trial in layman’s terms.
The EAST-STROKE (‘Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE’) trial is led by scientist from the University Medical Centre Hamburg-Eppendorf (UKE) and investigates whether early rhythm-control treatment can effectively and safely prevent strokes. The project is funded by the EU as part of ‘Horizon Europe’. AFNET is partner for dissemination and exploitation.
Patients with an acute stroke and atrial fibrillation have a particularly high risk of a recurrent stroke and other serious cardiovascular events. A Europe-wide clinical trial led by scientists from the University Medical Centre Hamburg-Eppendorf (UKE) is now investigating whether early rhythm-control treatment can effectively and safely prevent strokes.
On behalf of all our members, we would like to congratulate our AFNET founding member Prof Dr Meinertz on his 80th birthday! 🎈
We wish them all the best and good health for the coming years. Thank you very much for your great commitment and tireless dedication to AFNET!
Many patients with atrial fibrillation (AF) experience stroke, cardiovascular death and other cardiovascular complications. Early rhythm control can prevent some of these events but is often withheld from elderly patients with multiple comorbidities. Catheter ablation is the most effective rhythm-controlling therapy but has mainly been tested in younger patients. The German Atrial Fibrillation Network (AFNET) initiated the EASThigh – AFNET 11 trial to investigate whether early catheter ablation can reduce outcomes in patients with AF and comorbidities. EASThigh – AFNET 11 enrolled the first patient on 14.10.2024.
Atrial fibrillation (AF) epidemic affects the health of a growing number of people worldwide. Patients with AF are at risk of stroke, heart failure, death and dementia. Many patients develop AF in old age, and older people with cardiovascular comorbidities are at highest risk of AF-related complications.
A combined subgroup analysis of the similar trials NOAH – AFNET 6 (1) and ARTESiA (2) revealed: Patients with device-detected atrial fibrillation and concomitant vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from oral anticoagulation than those without vascular disease. The finding was presented by AFNET Steering Committee member Prof. Renate Schnabel, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, at the annual congress of the European Society of Cardiology (ESC) in London on 02.09.2024 and published in the European Heart Journal (3).
Device-detected atrial fibrillation (DDAF) are short and typically rare episodes of atrial fibrillation (AF) detected by pacemakers, defibrillators, or implanted loop recorders. Device-detected atrial fibrillation is found in every fifth patient with a cardiac implanted electronic device (4). Device-detected atrial fibrillation can lead to stroke, but the stroke risk in patients with device-detected atrial fibrillation appears lower than the stroke risk in patients with ECG-documented atrial fibrillation (1%/year).
Low concentrations of three selected biomarkers in the blood of patients with atrial fibrillation identify patients with a high chance of attaining sinus rhythm. This is the main result of this analysis of the EAST – AFNET 4 biomolecule study. Today the findings have been presented by AFNET Steering Committee member Prof. Larissa Fabritz, University Medical Center Hamburg Eppendorf (UKE), Hamburg, Germany, at the annual congress of the European Society of Cardiology (ESC) in London and published in the European Heart Journal (1).
Atrial Fibrillation (AF) is the most common arrhythmia in senior people. AF often occurs in patients with cardiovascular comorbidities. Recurrent AF is determined by interactions between cardiovascular disease processes and rhythm-control therapy. Predictors of attaining sinus rhythm at follow-up are not well known.
An international cardiology working group has published a consensus report on atrial cardiomyopathy (1). 21 scientists from the rhythmological societies of Europe (European Heart Rhythm Association (EHRA)), North America (Heart Rhythm Society (HRS)), South America (Latin American Heart Rhythm Society (LAHRS)) and the Asia-Pacific region (Asia Pacific Heart Rhythm Society APHRS) were involved. The expert group was led by AFNET board member Prof. Andreas Goette, Paderborn, Germany. He presented the results on August 31, 2024 at the annual congress of the European Society of Cardiology (ESC) in London.
Atrial cardiomyopathy (AtCM) refers to pathological changes in the heart’s atria, including the atrial muscle cells. They contribute to the development of atrial fibrillation, can cause blood clots and strokes and are therefore of fundamental clinical importance.
Prof Camm was honoured with the AFNET Lecture Award at the AFNET general meeting during the DGK 2025 annual conference in Mannheim. In this document you can see his lecture at the award ceremony.
